The influence of metformin in the etiology of selected cancers

Wspolczesna Onkologia

Volumn 16, Issue 3, 2012, Pages 223-229

  Pawałowska, Monika ^a   Markowska, Anna ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

AMPK; Diabetes; Metformin; mTOR; Oncological treatment

Indexed keywords

ANTINEOPLASTIC AGENT; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN; LIVER KINASE B1; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METFORMIN; PHENFORMIN; PHOSPHOTRANSFERASE; PROGESTERONE; SULFONYLUREA DERIVATIVE; UNCLASSIFIED DRUG;

ADD ON THERAPY; ANTIDIABETIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; CANCER MORTALITY; CANCER RISK; CARCINOGENESIS; CARDIOVASCULAR RISK; CELL GROWTH; CELL PROLIFERATION; COLORECTAL CANCER; DIABETES MELLITUS; DIARRHEA; DRUG EFFICACY; DYSLIPIDEMIA; ENDOMETRIUM CANCER; ENZYME ACTIVATION; FLATULENCE; GLUCOSE INTOLERANCE; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; LACTIC ACIDOSIS; META ANALYSIS (TOPIC); MORTALITY; NAUSEA; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OVARY POLYCYSTIC DISEASE; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN SYNTHESIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; RISK REDUCTION; SKIN DEFECT; TUMOR VOLUME; VOMITING;

EID: 84865069617     PISSN: 14282526     EISSN: None     Source Type: Journal    
DOI: 10.5114/wo.2012.29289     Document Type: Review

References (50)

1. Kim YI. Diet, lifestyle, and colorectal cancer: is hyperinsulinemia the missing link? Nutr Rev 1998; 56: 275-279.
2. Del Giudice ME, Fantus IG, Ezzat S, McKeown-Eyssen G, Page D, Goodwin PJ. Insulin and related factors in premenopausal breast cancer risk. Breast Cancer Res Treat 1998; 47: 111-120.
3. Yam D, Fink A, Mashiah A, Ben-Hur E. Hyperinsulinemia in colon, stomach, and breast cancer patients. Cancer Lett 1996; 104: 129-132.
4. Park SM, Lim MK, Shin SA, Yun YH. Impact of prediagnosis smoking, alcohol, obesity, and insulin resistance on survival in male cancer patients: National Health Insurance Corporation Study. J Clin Oncol 2006; 24: 5017-5024.
5. Gerstein HC. Does insulin therapy promote, reduce, or have a neutral effect on cancers? JAMA 2010; 303: 446-447.
6. Jee SH, Ohrr H, Sull JW, Yun JE, Ji M, Samet JM. Fasting serum glucose level and cancer risk in Korean men and women. JAMA 2005; 293: 194-202.
7. Pollak M. Insulin and insulin-like growth factor signaling in neoplasia. Nat Rev Cancer 2008; 8: 915-928.
8. Johnson JA, Bowker SL. Intensive glycaemic control and cancer risk in type 2 diabetes: a meta-analysis of major trials. Diabetologia 2011; 54: 25-31.
9. Tannock IF, Kopelyan I. Influence of glucose concentration on growth and formation of necrosis in spheroids derived from a human bladder cancer cell line. Cancer Res 1986; 46: 3105-3110.
10. LeRoith D, Baserga R, Helman L, Roberts CT Jr. Insulin-like growth factors and cancer. Ann Intern Med 1995; 122: 54-59.
11. United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ 1995; 310: 83-88.
12. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005; 330: 1304-1305.
13. Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 2009; 32: 1620-1625.
14. Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 2006; 29: 254-258.
15. Decensi A, Puntoni M, Goodwin P, Cazzaniga M, Gennari A, Bonanni B, Gandini S. Metformin and cancer risk in diabetic patients: a systemic review and meta-analysis. Cancer Prev Res (Phila) 2010; 3: 1451-1461.
16. Witters LA. The blooming of the French lilac. J Clin Invest 2001; 108: 1105-1107.
17. Hadden DR. Goat's rue - French lilac - Italian fitch - Spanish sain-foin: gallega officinalis and metformin: the Edinburgh connection. J R Coll Physicians Edinb 2005; 35: 258-260.
18. Bailey CJ, Day C. Metformin: its botanical background. Pract Diab Int 2004; 21: 115-117.
19. Tessari P, Tiengo A. Metformin treatment of rats with diet induced overweight and hypertriglyceridemia decreases plasma triglyceride concentrations, while decreasing triglyceride and increasing ketone body output by the isolated perfused liver. Acta Diabetol 2008; 45: 143-145.
20. Ng EH, Wat NM, Ho PC. Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomipheneresistant polycystic ovaries: a randomized, double-blinded placebo-controlled trial. Hum Reprod 2001; 16: 1625-1631.
21. Fleming R, Hopkinson ZE, Wallace AM, Greer IA, Sattar N. Ovarian function and metabolic factors in women with oligomenorrhoea treated with metformin in a randomized double blind placebo-controlled trial. J Clin Endocrinol Metab 2002; 87: 569-574.
22. Steinberg GR, Kemp BE. AMPK in health and disease. Physiol Rev 2009; 89: 1025-1078.
23. Hardie DG. AMP-activated/SNF1protein kinases: conserved guardians of cellular energy. Nat Rev Mol Cell Biol 2007; 8: 774-785.
24. Shaw RJ, Lamia KA, Vasquez D, Koo SH, Bardeesy N, Depinho RA, Montminy M, Cantley LC. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 2005; 310: 1642-1646.
25. Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res 2007; 67: 10804-10812.
26. Gotlieb WH, Saumet J, Beauchamp MC, Gu J, Lau S, Pollak MN, Bruchim I. In vitro metformin anti-neoplastic activity in epithelial ovarian cancer. Gynecol Oncol 2008; 110: 246-250.
27. Kalender A, Selvaraj A, Kim SY, et al. Metformin, independent of AMPK, inhibits mTORC1 in rag GTPase-dependent manner. Cell Metab 2010; 11: 390-401.
28. Liang J, Shao SH, Xu ZX, et al. The energy sensing LKB1-AMPK pathway regulates p27(kip1) phesphorylation mediating the decision to enter authophagy or apoptosis. Nat Cell Biol 2007; 9: 218-224.
29. Lee MS, Hsu CC, Wahlqvist ML, Tsai HN, Chang YH, Huang YC. Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a retrospective population prospective cohort study of 800 000 individuals. BMC Cancer 2011; 11: 20.
30. Bosco JL, Antonsen S, Sørensen HT, Pedersen L, Lash TL. Metformin and incident breast cancer among diabetic women: a population-based control-case study in Denmark. Cancer Epidemiol Biomarkers Prev 2011; 20: 101-111.
31. Thor A, Anderson SM. Clinical studies of metformin action in breast cancer. Am J Clin Oncol 2011. Educational book: 46-49.
32. Jiralerspong S, Palla SL, Giordano SH, et al. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 2009; 27: 3297-3302.
33. Alimova IN, Liu B, Fan Z, Edgerton SM, Dillon T, Lind SE, Thor AD. Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle 2009; 8: 909-915.
34. Schwartz GK, Shah MA. Targeting the cell cycle: a new approach to cancer therapy. J Clin Oncol 2008; 23: 9408-9421.
35. Zhuang Y, Miskimins WK. Metformin induces both caspase-dependent and poly(ADP-ribose) polymerase-dependent cell death in breast cancer cells. Mol Cancer Res 2011; 9: 603-615.
36. Liu B, Fan Z, Edgerton SM, Deng XS, Alimova IN, Lind SE, Thor AD. Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle 2009; 8: 2031-2040.
37. Berstein LM, Boyarkina MP, Tsyrlina EV, Turkevich EA, Semiglazov VF. More favorable progesterone receptor phenotype of breast cancer in diabetics treated with metformin. Med Oncol 2011; 28: 1260-1263.
38. Garcia A, Tisman G. Metformin, B(12) and enhanced breast cancer response to chemotherapy. J Clin Oncol 2010; 28: e19.
39. Grenader T, Goldberg A, Shavit L. Metformin as an addition to conventional chemotherapy in breast cancer. J Clin Oncol 2009; 27: e259.
40. Guppy A, Jamal-Hanjani M, Pickering L. Anticancer effects of metformin and its potential use as a therapeutic agent for breast cancer. Future Oncol 2011; 7: 727-736.
41. Goodwin PJ, Stambolic V. Metformin, cancer risk and prognosis. Am J Clin Oncol 2011. Educational book: 42-45.
42. Renehan A, Smith U, Kirkman MS. Linking diabetes and cancer: a consensus on complexity. Lancet 2010; 375: 2201-2202.
43. Bird RP. Role of aberrant crypt foci in understanding the pathogenesis of colon cancer. Cancer Lett 1995; 93: 55-71.
44. Hosono K, Endo H, Takahashi H, et al. Metformin suppresses azoxymethane-induced colorectal aberrant crypt foci by activating AMP-activated protein kinase. Mol Carcinog 2010; 49: 662-671.
45. Tomimoto A, Endo H, Sugiyama M, et al. Metformin suppresses intestinal polyp growth in ApcMin/+ mice. Cancer Sci 2008; 99: 2136-2141.
46. Hwang JT, Ha J, Park IJ, Lee SK, Baik HW, Kim YM, Park OJ. Apoptotic effect of EGCG in HT-29 colon cancer via AMPK signal pathway. Cancer Lett 2007; 247: 115-121.
47. Buzzai M, Jones RG, Amaravadi RK, et al. Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res 2007; 67: 6745-6752.
48. Li D, Yeung SC, Hassan MM, Konopleva M, Abbruzzese JL. Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology 2009; 137: 482-488.
49. Cui X, Zhang P, Deng W, Oesterreich S, Lu Y, Mills GB, Lee AV. Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity in breast cancer. Mol Endocrinol 2003; 17: 575-588.
50. Xie Y, Wang YL, Yu L, Hu Q, Ji L, Zhang Y, Liao QP. Metformin promotes progesterone receptor expression via inhibition of mammalian target of rapamycin (mTOR) in endometrial cancer cells. J Steroid Biochem Mol Biol 2011; 126: 113-120.